Download - CARCINOMA MICROCÍTICO DE PULMÓN
![Page 1: CARCINOMA MICROCÍTICO DE PULMÓN](https://reader035.vdocument.in/reader035/viewer/2022072310/62dad4b7ed44c172c4754b04/html5/thumbnails/1.jpg)
![Page 2: CARCINOMA MICROCÍTICO DE PULMÓN](https://reader035.vdocument.in/reader035/viewer/2022072310/62dad4b7ed44c172c4754b04/html5/thumbnails/2.jpg)
Dr. Javier Garde
Día 2
Carcinoma microcítico y mesotelioma
![Page 3: CARCINOMA MICROCÍTICO DE PULMÓN](https://reader035.vdocument.in/reader035/viewer/2022072310/62dad4b7ed44c172c4754b04/html5/thumbnails/3.jpg)
Índice
CARCINOMA MICROCÍTICO DE PULMÓN
• ABSTRACT 8515: DURVALUMAB-TREMELIMUMAB +/- SBRT
• ABSTRACT 8516: Rova-T + NIVOLUMAB +/- IPILIMUMAB
MESOTELIOMA
• ABSTRACT 8517: Pemetrexed de mantenimiento
![Page 4: CARCINOMA MICROCÍTICO DE PULMÓN](https://reader035.vdocument.in/reader035/viewer/2022072310/62dad4b7ed44c172c4754b04/html5/thumbnails/4.jpg)
Durvalumab + Tremelimumab +/- SBRT
Abstract 8515, Owinikoko et al, ASCO 2019 A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients withrelapsed small cell lung cáncer (SCLC)
![Page 5: CARCINOMA MICROCÍTICO DE PULMÓN](https://reader035.vdocument.in/reader035/viewer/2022072310/62dad4b7ed44c172c4754b04/html5/thumbnails/5.jpg)
Abstract 8516, Malhotra et al, BOARD 272: Ph172 study of Rova-t in combination with Nivolumab (Nivo) +/- ipilimumab (Ipi) for patients with 2L+ extensive-stage (ED) SCLC.
Rova-T + Nivolumab +/- Ipilimumab
![Page 6: CARCINOMA MICROCÍTICO DE PULMÓN](https://reader035.vdocument.in/reader035/viewer/2022072310/62dad4b7ed44c172c4754b04/html5/thumbnails/6.jpg)
![Page 7: CARCINOMA MICROCÍTICO DE PULMÓN](https://reader035.vdocument.in/reader035/viewer/2022072310/62dad4b7ed44c172c4754b04/html5/thumbnails/7.jpg)
Mesotelioma: Mantenimiento con Pemetrexed?
Abstract 8517. Arkadiusz Z, et al, Randomized phase 2 study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after firrst-line chemotherapy: Cancer and Leukemia Group (CALGB) 30901 (Alliance)